pimicotinib

Search documents
大行评级|花旗:大幅上调和誉目标价至25港元 维持“买入”评级
Ge Long Hui· 2025-09-23 05:45
该行认为,当前估值仅反映其两款后期候选药物pimicotinib及irpagratinib价值,其具高授权潜力的差异 化创新药则尚未被市场充分认可。 ABSK043可与靶向疗法联合使用,且无重大安全性问题,为患者提 供口服治疗方案。其KRAS系列药物,包括ABSK141和ABSK211,已展示良好口服生物利用度和体内疗 效,并将于下半年至明年进入临床阶段。和誉正开发超越肿瘤学的更多候选药物,其中心血管代谢疾病 药P151已进入IND启动阶段。 该行将和誉目标价由17.5港元上调至25港元,维持"买入"评级。 花旗发表报告指,尽管和誉股价今年累升280%,但在该行覆盖的生物科技股中仍属被低估。 ...
港股异动 | 和誉-B(02256)涨超9%再创新高 月内累涨逾60% 公司获纳入MSCI全球小型股指数
智通财经网· 2025-08-19 05:49
Core Viewpoint - The stock of He Yu-B (02256) has seen significant gains, rising over 60% in the month, driven by its inclusion in the MSCI Global Small Cap Index and strong financial performance [1] Group 1: Stock Performance - He Yu-B's stock price reached a new high of 17.5 HKD, with a current increase of 6.37% to 17.03 HKD [1] - The stock has experienced a cumulative increase of over 60% within the month [1] Group 2: MSCI Inclusion - On August 13, He Yu-B announced its inclusion in the MSCI Global Small Cap Index, effective after the market close on August 26 [1] - This inclusion is expected to lead to increased buying from passive funds, such as ETFs, enhancing market liquidity and international visibility for the company [1] Group 3: Financial Performance - For the first half of the year, He Yu-B reported revenue of 612 million HKD, representing a year-on-year growth of 23% [1] - The company's profit reached 328 million HKD, marking a year-on-year increase of 59% [1] - The strong performance was attributed to higher-than-expected income from Merck's exercise [1] Group 4: Analyst Insights - CICC noted that the company's performance exceeded expectations, while Citigroup highlighted that the current valuation is low [1] - Citigroup emphasized the high certainty of the late-stage candidates pimicotinib and irpagratinib, suggesting potential for external licensing [1] - The firm anticipates a high success rate for the Phase III clinical trial of irpagratinib for second-line liver cancer, which should be factored into the company's valuation [1]
和誉-B涨超9%再创新高 月内累涨逾60% 公司获纳入MSCI全球小型股指数
Zhi Tong Cai Jing· 2025-08-19 05:46
Core Viewpoint - The stock of He Yu-B (02256) has seen significant gains, rising over 60% in the month, driven by its inclusion in the MSCI Global Small Cap Index and strong financial performance [1] Group 1: Stock Performance - He Yu-B's stock price reached a new high of 17.5 HKD, with a current increase of 6.37% to 17.03 HKD [1] - The stock has experienced a cumulative increase of over 60% within the month [1] Group 2: MSCI Inclusion - On August 13, He Yu-B announced its inclusion in the MSCI Global Small Cap Index, effective after the market close on August 26 [1] - This inclusion is expected to lead to increased buying from passive funds, such as ETFs, enhancing market liquidity and international visibility for the company [1] Group 3: Financial Performance - For the first half of the year, He Yu-B reported revenue of 612 million HKD, representing a year-on-year growth of 23% [1] - The company's profit reached 328 million HKD, marking a year-on-year increase of 59% [1] - The strong performance was attributed to better-than-expected income from Merck's exercise [1] Group 4: Analyst Insights - CICC noted that the company's performance exceeded expectations, while Citigroup highlighted that the current valuation is low [1] - Citigroup emphasized the high certainty of the late-stage candidates, pimicotinib and irpagratinib, and the potential for differentiated innovation pipelines to secure external licensing [1] - The success rate of the Phase III clinical trial for irpagratinib in second-line liver cancer is expected to be very high, which should be factored into the company's valuation [1]
港股异动 和誉-B(02256)再涨超4% 股价续刷历史新高 年内股价累涨近两倍
Jin Rong Jie· 2025-08-12 07:14
Core Viewpoint - The stock of He Yu-B (02256) has risen over 4%, reaching a historical high of 13.67 HKD, with a year-to-date increase of nearly 100% [1] Financial Performance - For the first half of the year, the company reported revenue of 612 million RMB, representing a year-on-year growth of 21.5% [1] - The net profit attributable to shareholders was 328 million RMB, showing a significant increase of 58.8% year-on-year [1] Research and Development - The company has increased its R&D expenses by 6% year-on-year, while reducing management fees by 13%, leading to improved profitability [1] Financial Guidance - The company has guided that its operating cash consumption for the year will remain within 570 million RMB, with expectations of maintaining profitability [1] Market Valuation - Citigroup believes that the current valuation of He Yu is low, considering the high certainty of its two late-stage drug candidates, pimicotinib and irpagratinib, and the potential for differentiated innovative pipelines to achieve external licensing [1] Future Catalysts - Key catalysts are anticipated in 2025 and 2026, including the approval and commercialization of pimicotinib, the release of phase III data for irpagratinib in second-line liver cancer, and updates on several other drug candidates [1]
和誉-B再涨超4% 股价续刷历史新高 年内股价累涨近两倍
Zhi Tong Cai Jing· 2025-08-12 06:43
Core Viewpoint - The stock of He Yu-B (02256) has risen over 4%, reaching a historical high of 13.67 HKD, with a year-to-date increase of nearly 100% [1] Financial Performance - For the first half of the year, the company reported revenue of 612 million RMB, representing a year-on-year growth of 21.5% [1] - The net profit attributable to shareholders was 328 million RMB, showing a significant year-on-year increase of 58.8% [1] Research and Development - The company has increased its R&D expenses by 6% year-on-year, indicating a commitment to innovation [1] - Management expenses have decreased by 13%, contributing to improved profitability [1] Financial Guidance - The company has guided that its operating cash consumption will remain within 570 million RMB for the year, suggesting a stable financial outlook [1] Market Valuation and Future Prospects - Citigroup believes the current valuation of He Yu is low, considering the high certainty of its two late-stage drug candidates, pimicotinib and irpagratinib [1] - The success rate of the phase III clinical trial for irpagratinib in second-line liver cancer is expected to be very high, which should be factored into the company's valuation [1] Key Catalysts - Citigroup anticipates key catalysts for the company in 2025 and 2026, including the approval and commercialization of pimicotinib, the release of phase III data for irpagratinib, and updates on several other drug candidates [1]
港股异动 | 和誉-B(02256)再涨超4% 股价续刷历史新高 年内股价累涨近两倍
智通财经网· 2025-08-12 06:43
Core Viewpoint - He Yu-B (02256) has seen its stock price rise over 4%, reaching a historical high of 13.67 HKD, with a year-to-date increase of nearly 100% [1] Financial Performance - For the first half of the year, the company reported revenue of 612 million RMB, representing a year-on-year growth of 21.5% [1] - The net profit attributable to shareholders was 328 million RMB, showing a significant year-on-year increase of 58.8% [1] Research and Development - The company has increased its R&D expenses by 6% year-on-year, indicating a commitment to innovation [1] - Management expenses have decreased by 13%, contributing to improved profitability [1] Financial Guidance - The company has guided that its operating cash consumption for the year will remain within 570 million RMB, with expectations of maintaining profitability [1] Market Valuation and Future Prospects - Citigroup believes the current valuation of He Yu-B is low, considering the high certainty of its two late-stage drug candidates, pimicotinib and irpagratinib [1] - The success rate of the phase III clinical trial for irpagratinib in second-line liver cancer is expected to be very high, which should be factored into its valuation [1] - Key catalysts are anticipated in 2025 and 2026, including the approval and commercialization of pimicotinib, phase III data for irpagratinib, and updates on other candidates like ABSK043 and ABSK061 [1]
港股异动|和誉-B(02256)涨超4%续创新高 上半年业绩快速增长 花旗称公司现估值偏低
Jin Rong Jie· 2025-08-11 06:06
Group 1 - The core viewpoint of the articles highlights the strong performance of He Yu-B (02256), with its stock price reaching a historical high of 12.89 HKD, reflecting a rise of over 4% [1] - The company reported a revenue of 612 million HKD for the first half of the year, representing a year-on-year growth of 21.5%, and a net profit attributable to shareholders of 328 million HKD, which is a 58.8% increase year-on-year [1] - He Yu plans to implement a share buyback program starting from March 2025, having already repurchased 9.545 million shares, accounting for 1.4% of the total shares issued at the beginning of the year, with a total expenditure of 75.3 million HKD [1] Group 2 - Citigroup believes that He Yu's current valuation is low, considering the high certainty of its two late-stage drug candidates, pimicotinib and irpagratinib, and the potential for differentiated innovative pipelines to achieve external licensing [2] - The bank anticipates a high success rate for the phase III clinical trial of irpagratinib for second-line hepatocellular carcinoma, suggesting that this should be factored into the company's valuation [2] - Key catalysts are expected for He Yu in 2025 and 2026, including the approval and commercialization performance of pimicotinib, the announcement of phase III data for irpagratinib, and updates on multiple candidate drugs such as ABSK043 and ABSK061, along with potential commercial collaborations [2]
港股异动 | 和誉-B(02256)涨超4%续创新高 上半年业绩快速增长 花旗称公司现估值偏低
智通财经网· 2025-08-11 05:39
Group 1 - The core viewpoint of the articles highlights the strong performance of He Yu-B (02256), with a significant stock price increase and positive mid-year financial results [1][2] - He Yu reported a revenue of 612 million yuan, representing a year-on-year growth of 21.5%, and a net profit attributable to shareholders of 328 million yuan, reflecting a 58.8% increase [1] - The company has initiated a share buyback plan starting from March 2025, having repurchased 9.545 million shares, which is 1.4% of the total shares issued at the beginning of the year, involving a total expenditure of 75.3 million HKD [1] Group 2 - Citigroup believes that He Yu's current valuation is low, considering the high certainty of its two late-stage drug candidates, pimicotinib and irpagratinib, and the potential for differentiated innovation pipeline to achieve external licensing [2] - The bank anticipates a high success rate for the phase III clinical trial of irpagratinib for second-line hepatocellular carcinoma, suggesting that this should be factored into the company's valuation [2] - Key catalysts are expected for He Yu in 2025 and 2026, including the approval and commercialization performance of pimicotinib, the announcement of phase III data for irpagratinib, and updates on several other drug candidates [2]
大行评级|花旗:上调和誉目标价至17.5港元 维持“买入”评级
Ge Long Hui· 2025-08-11 03:44
Core Viewpoint - Citigroup's research report indicates that He Yu's current valuation is undervalued, supported by the high certainty of its two late-stage candidates, pimicotinib and irpagratinib, along with a differentiated innovation pipeline that is expected to achieve external licensing opportunities [1] Group 1: Drug Candidates and Clinical Trials - The firm anticipates a high success rate for the phase III clinical trial of irpagratinib for second-line hepatocellular carcinoma, which should be factored into the valuation [1] - Key catalysts for He Yu are expected in 2025 and 2026, focusing on the approval and commercialization performance of pimicotinib, the announcement of phase III data for irpagratinib, and updates on multiple candidates such as ABSK043 and ABSK061, along with potential commercial collaborations [1] Group 2: Financial Projections - The revenue forecast for He Yu in 2026 has been adjusted down from 289 million to 280 million, while the earnings per share loss estimate has been revised from 0.38 to 0.39 [1] - For 2027, the projected revenue and earnings per share loss are expected to be 452 million and 0.34, respectively [1] - The firm maintains a "Buy" rating, raising the target price from 10 HKD to 17.5 HKD [1]
摩根士丹利:中国医疗保健_每周快报
摩根· 2025-06-23 02:10
Investment Rating - The report rates the China Healthcare industry as Attractive [4]. Core Insights - The National Health Commission (NHC) has published guidelines for the "2025 Tertiary Hospital Accreditation Standards," focusing on enhancing hospital accreditation processes and supporting primary healthcare institutions [2]. - WuXi Biologics has begun construction of a microbial manufacturing facility in Chengdu, featuring a 15,000L fermentation tank with an annual production capacity of 80-110 drug substance batches and potential expansion to 60,000L [2]. - The National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation for Sac-TMT in combination with tagitanlimab for treating non-squamous non-small cell lung cancer [2]. Summary by Sections Regulatory Developments - The NHC's guidelines aim to improve tertiary hospital capabilities, emphasizing critical medical services and innovation [2]. Company Updates - WuXi Biologics' new facility will be the first in China to have a two-chamber lyophilization line, capable of producing over 10 million bottles of drug product annually [2]. - Other companies like Kelun Bio and Huadong Medicine have received NMPA approvals for clinical trials, indicating ongoing innovation in the sector [8]. Market Trends - The report highlights a decline in net fund flows in the healthcare sector, with a net outflow of RMB 2,476,000 in the past week, reflecting a cautious investor sentiment [15][16].